» Articles » PMID: 22140659

Cytokeratin-18 and Hyaluronic Acid Levels Predict Liver Fibrosis in Children with Non-alcoholic Fatty Liver Disease

Overview
Specialty Biochemistry
Date 2011 Dec 6
PMID 22140659
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: There is a need to replace liver biopsy with non-invasive markers that predict the degree of liver fibrosis in fatty liver disease related to obesity. Therefore, we studied four potential serum markers of liver fibrosis and compared them with histopathological findings in liver biopsy in children with non-alcoholic fatty liver disease (NAFLD).

Methods: We determined fasting serum level of hyaluronic acid (HA), laminin, YKL-40 and cytokeratin-18 M30 in 52 children (age range 4-19, mean 12 years, 80 % of them were overweight or obese) with biopsy-verified NAFLD. Viral hepatitis, autoimmune and metabolic liver diseases (Wilson's disease, alpha-1-antitrypsin deficiency, cystic fibrosis) were excluded. Fibrosis stage was assessed in a blinded fashion by one pathologist according to Kleiner. Receiver operating characteristics (ROC) analysis was used to calculate the power of the assays to detect liver fibrosis (AccuROC, Canada).

Results: Liver fibrosis was diagnosed in 19 children (37 %). The levels of HA and CK18M30 were significantly higher in children with fibrosis compared to children without fibrosis (p=0.04 and 0.05 respectively). The ability of serum HA (cut-off 19.1 ng/ml, Se=84 %, Sp=55 %, PPV=52 %, NPV=86 %) and CK18M30 (cut-off 210 u/l, Se=79 %, Sp=60 %, PPV=56 %, NPV=82 %) to differentiate children with fibrosis from those without fibrosis was significant (AUC=0.672 and 0.666, respectively). The combination of both markers was superior (AUC=0.73, p=0.002). Laminin and YKL-40 levels did not allow a useful prediction.

Conclusions: Cytokeratin-18 and hyaluronic acid are suitable serum markers predicting liver fibrosis in children with NAFLD. Studying these markers may identify patients at risk of disease progression.

Citing Articles

Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective.

Gurjar S, Bhat A R, Upadhya R, Shenoy R Lipids Health Dis. 2025; 24(1):5.

PMID: 39773634 PMC: 11705780. DOI: 10.1186/s12944-024-02396-3.


Clinical validation of preoperative serum markers for liver fibrosis in living donor liver transplantation recipients.

Tomino T, Itoh S, Toshima T, Yoshiya S, Bekki Y, Iseda N Surg Today. 2024; .

PMID: 39317845 DOI: 10.1007/s00595-024-02941-8.


KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease.

Kim M, Han J, An J, Kim B, Jin Y, Kim S Clin Mol Hepatol. 2024; 30(Suppl):S5-S105.

PMID: 39159947 PMC: 11493350. DOI: 10.3350/cmh.2024.0506.


Liver Fat Scores for Noninvasive Diagnosis and Monitoring of Nonalcoholic Fatty Liver Disease in Epidemiological and Clinical Studies.

Reinshagen M, Kabisch S, Pfeiffer A, Spranger J J Clin Transl Hepatol. 2023; 11(5):1212-1227.

PMID: 37577225 PMC: 10412706. DOI: 10.14218/JCTH.2022.00019.


Association of Non-Invasive Markers with Significant Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study.

Zhang F, Han Y, Zheng L, Liu J, Wu Y, Bao Z Diabetes Metab Syndr Obes. 2023; 16:2255-2268.

PMID: 37545743 PMC: 10403050. DOI: 10.2147/DMSO.S417754.